Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity

Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity

Abstract Background The study characterizes safety, tolerability, pharmacokinetic and pharmacodynamic profiles of single rising doses of the 11beta-hydroxysteroid dehydrogenase-1 (11beta-HSD1) inhibitor BI 187004 in healthy men with overweight or obesity. Methods This was a randomized, double-blind,...

Full description

Bibliographic Details
Main Authors: Susanna Bianzano, Tim Heise, Arvid Jungnik, Cornelia Schepers, Corinna Schölch, Ulrike Gräfe-Mody
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Clinical Diabetes and Endocrinology
Subjects:
11beta-Hydroxysteroid dehydrogynase-1 inhibitor
Single rising dose
Pharmacokinetics
Pharmacodynamics
Type 2 diabetes
BI 187004
Online Access:https://doi.org/10.1186/s40842-021-00130-x

Similar Items

Similar Items